SAPHIR : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases (SAPHIR)
Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases
Sponsor: Fresenius Kabi, France
This observational or N/A phase trial investigates Ankylosing Spondylitis and Crohn Disease and is currently ongoing. Fresenius Kabi, France leads this study, which shows 8 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Feb 2026 — Present [monthly]
Unknown
Status: Recruiting → Unknown
-
Sep 2025 — Feb 2026 [monthly]
Recruiting
-
Sep 2024 — Sep 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
May 2024 — Jul 2024 [monthly]
Recruiting
▶ Show 3 earlier versions
-
Aug 2023 — May 2024 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Dec 2022 — Aug 2023 [monthly]
Not Yet Recruiting
-
Nov 2022 — Dec 2022 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Fresenius Kabi, France
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alès, France , Amiens, France , Argeles, France , Armentières, France , Aubenas, France , Bayonne, France , Besançon, France , Bois-Guillaume, France , Boulogne-Billancourt, France , Boulogne-sur-Mer, France and 63 more locations